SecBot SecBot
SECBOTREPLAY Home › Report › SLNO

SLNO · Soleno Therapeutics has voluntarily withdrawn its marketing…

SOLENO THERAPEUTICS INC · 8-K filed Apr 7, 2026 at 06:58 ET

At the news

BEARISHIMPACT 7/10

8-K filed Apr 7, 2026 at 06:58 ET

Soleno Therapeutics has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT (VYKATTM XR) in Europe for Prader-Willi syndrome, citing business and strategic considerations. The decision preserves the option to re-engage with regulators in the future, but removes near-term commercial prospects in Europe.

  • Soleno Therapeutics withdrew its MAA for VIOKAT (diazoxide choline) in Europe for Prader-Willi syndrome (PWS).
  • The application was under review by the European Medicines Agency (EMA) with a decision expected in mid-2026.
  • The withdrawal was voluntary and based on 'business and strategic considerations'.
  • The company retains the ability to re-engage with regulators in the future if a viable pathway emerges.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access